There is a concerted research effort to investigate brain mechanisms underlying addiction processes that may predicate the development of new compounds for treating addiction. One target is the brain's opioid system, because of its role in the reinforcing effects of substances of abuse. Substance-dependent populations have increased numbers of the mu opioid receptor (MOR) in fronto-striatal regions that predict drug relapse, and demonstrate disturbances in these regions during the processing of non-drug rewards. Naltrexone is currently licensed for alcohol and opiate dependence, and may remediate such disturbances through the blockade of MORs in fronto-striatal reward circuitry. Therefore, we examined the potential acute modulating effects ...
Context—Medication treatment of alcoholism is presently not particularly robust. Neuroimaging techni...
Relapse to alcohol addiction after prolonged withdrawal periods is a major problem in the treatment ...
Injectable extended-release naltrexone (XRNTX) presents an effective therapeutic strategy for opioid...
There is a concerted research effort to investigate brain mechanisms underlying addiction processes ...
Identifying key neural substrates in addiction disorders for targeted drug development remains a maj...
Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence. Although t...
Naltrexone, an opioid receptor antagonist, is commonly used as a relapse prevention medication in al...
Interactions between dopaminergic and opioidergic systems have been implicated in the reinforcing pr...
AbstractOral naltrexone reduces heavy drinking, but is less consistent as an abstinence promoter, wh...
Identifying key neural substrates in addiction disorders for targeted drug development remains a maj...
Background Nalmefene (Selincro®) is a µ- and δ- opioid receptor antagonist, κ-opioid receptor partia...
During the first weeks of abstinence, alcohol craving in patients may increase or “incubate.” We hyp...
Background: Emerging evidence suggests that opioid receptor antagonists, such as naltrexone, are eff...
Addiction theories posit long-term alterations in reward systems from repeated activation of these a...
Previously, we found that distinct brain areas predict individual selection bias in decisions betwee...
Context—Medication treatment of alcoholism is presently not particularly robust. Neuroimaging techni...
Relapse to alcohol addiction after prolonged withdrawal periods is a major problem in the treatment ...
Injectable extended-release naltrexone (XRNTX) presents an effective therapeutic strategy for opioid...
There is a concerted research effort to investigate brain mechanisms underlying addiction processes ...
Identifying key neural substrates in addiction disorders for targeted drug development remains a maj...
Naltrexone is an opioid receptor antagonist used in the management of alcohol dependence. Although t...
Naltrexone, an opioid receptor antagonist, is commonly used as a relapse prevention medication in al...
Interactions between dopaminergic and opioidergic systems have been implicated in the reinforcing pr...
AbstractOral naltrexone reduces heavy drinking, but is less consistent as an abstinence promoter, wh...
Identifying key neural substrates in addiction disorders for targeted drug development remains a maj...
Background Nalmefene (Selincro®) is a µ- and δ- opioid receptor antagonist, κ-opioid receptor partia...
During the first weeks of abstinence, alcohol craving in patients may increase or “incubate.” We hyp...
Background: Emerging evidence suggests that opioid receptor antagonists, such as naltrexone, are eff...
Addiction theories posit long-term alterations in reward systems from repeated activation of these a...
Previously, we found that distinct brain areas predict individual selection bias in decisions betwee...
Context—Medication treatment of alcoholism is presently not particularly robust. Neuroimaging techni...
Relapse to alcohol addiction after prolonged withdrawal periods is a major problem in the treatment ...
Injectable extended-release naltrexone (XRNTX) presents an effective therapeutic strategy for opioid...